KALA BIO, Inc. (KALA)
KALANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.1699
-0.0074 (-4.17%) today
Regular session, Nov 10, 3:04 PM ET
- Market cap
- $3.29m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $0.1600 to $0.1800
- 52-week range
- $0.1146 to $95.50
- Average volume
- 1.85m
- Previous close
- $0.1773
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$7.24m | -$10.22m | -$1.80m | -$1.72m |
| Net income | -$7.56m | $686.0k | -$1.62m | -$1.58m |
News
8 latest- KALA BIO, Inc. Reports Preliminary Third Quarter 2026 Financial ResultsFintel · 23 hours ago
- KALA BIO, Inc. Stockholders Approve Reverse Stock Split Amendment of Between 1-for-2 and 1-for-300Fintel · 7 days ago
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data RTTNews · Oct 2, 2026
- KALA Bio Signs LOI To Acquire Nationwide Telehealth Platform; Shares Rise RTTNews · Sep 30, 2026
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study RTTNews · Sep 25, 2026
- Kala Bio And Virotek Sign LOI To Expand Genetic Testing Distribution RTTNews · Sep 24, 2026
- Kala Bio Signs LOI With Virotek For Exclusive U.S. Distribution; Stock Down RTTNews · Sep 1, 2026
- Kala Bio Surges 75% On AI Healthcare Breakthrough RTTNews · Mar 11, 2026
The company
KALA BIO, Inc. (NASDAQ: KALA) is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company's dual strategy combines a proprietary biologics pipeline-including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates-with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments. KALA also holds exclusive U.S. distribution rights for Virotek's ophthalmology genetic testing program and is evaluating acquisitions of revenue-generating healthcare businesses.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- kalarx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.